Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/4262
Title: 5-Fluorouracil increases the number and complexity of premature complexes in the heart: A prospective study using ambulatory ECG monitoring
Authors: Yilmaz, U.
Oztop, I.
Ciloglu, A.
Okan, T.
Tekin, U.
Yaren, Arzu.
Somali, I.
Keywords: antihypertensive agent
antineoplastic agent
fluorouracil
folinic acid
heart enzyme
oral antidiabetic agent
adjuvant therapy
adult
aged
ambulatory monitoring
article
cancer adjuvant therapy
cancer combination chemotherapy
cardiotoxicity
clinical article
clinical observation
clinical trial
continuous infusion
diabetes mellitus
digestive system cancer
drug safety
esophagus cancer
female
heart rate
heart rhythm
heart ventricle extrasystole
Holter monitoring
human
hypertension
liver cancer
loading drug dose
male
medical record review
metastasis
multiple cycle treatment
patient assessment
priority journal
side effect
ST segment
stomach cancer
supraventricular premature beat
symptom
thorax pain
Adult
Aged
Antimetabolites, Antineoplastic
Cardiac Complexes, Premature
Electrocardiography, Ambulatory
Female
Fluorouracil
Gastrointestinal Neoplasms
Humans
Male
Middle Aged
Prospective Studies
Abstract: The cardiac toxicity of LV5FU2 (de Gramont) regimen which is a widely used chemotherapy regimen in gastrointestinal system cancers is not well defined. We aimed to evaluate the impact of this regimen on cardiac rhythm. Two Holter ECG recordings were obtained in all patients with gastrointestinal system cancers treated with LV5FU2 regimen as first-line chemotherapy (one before and the second during the first 24 h of chemotherapy). Records were reviewed for the heart rate, rhythm, atrial premature complexes (APC), ventricular premature complexes (VPC), grades according to Lown-Wolf grading system and ST segment changes. Holter ECG recordings were evaluated in 27 patients. In the baseline evaluation, neither clinical symptom nor ST segment changes were observed. During the treatment period, chest pain was observed in two patients without any cardiac enzyme and ST segment changes. Moreover, a decrease in mean heart rate, and an increase in the number and complexity of premature complexes secondary to treatment were observed. The mean heart rate, APC per hour and VPC per hour (±SD) before vs. during treatment were, respectively, 93.1 ± 16.4 vs. 81.6 ± 12.7 (p = 0.001), 18.9 ± 54.0 vs. 45.3 ± 53.8 vs. (p = 0.049) and 12.7 ± 29.6 vs. 38.1 ± 42.1 (p = 0.002). LV5FU2 regimen leads to a decrease in mean heart rate and a significant increase in APC and VPC which may lead to serious arrhythmias. These effects must be better understood for a safer administration of this useful and widely used drug regimen. © 2007 The Authors.
URI: https://hdl.handle.net/11499/4262
https://doi.org/10.1111/j.1742-1241.2007.01323.x
ISSN: 1368-5031
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

36
checked on Jun 1, 2024

WEB OF SCIENCETM
Citations

33
checked on Jun 7, 2024

Page view(s)

48
checked on May 27, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.